Targeted Therapies in the Treatment of Sarcomas

AbstractAbout 50% of sarcomas have specific pathology-defining molecular alterations including mutations, fusion genes, and gene amplifications. Some of these alterations appear to be oncogenic drivers, and a subset can be utilized as targets for standard or experimental molecularly targeted agents in the clinic. In addition, immunotherapies may have a growing role in the treatment of sarcomas in the future.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research